NYSE - Delayed Quote USD

Boston Scientific Corporation (BSX)

67.42

-0.54

(-0.79%)

At close: April 18 at 4:00 PM EDT

67.06

-0.36

(-0.53%)

Pre-Market: 7:15 AM EDT

FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'

On Wednesday, Boston Scientific Corporation (NYSE:BSX) said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. An investigation determined that delivery of Obsidio Embolic using the aliquot technique, a commonly used delivery method in embolization procedures, for lower gastrointestinal (GI) bleeding embolization, implies a high risk of bowel ischemia. The most serious and the most common adverse health consequenc

Benzinga 19 hours ago

BSX
-0.79%
Boston Scientific recalls blood-blocking agent linked to 2 deaths

Seven injuries and 11 incidents were also associated with the safety issue.

MedTech Dive yesterday

BSX
-0.79%
UPDATE 1-FDA classifies recall of Boston Scientific device as 'most serious'

The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as "most serious". An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding, the agency said. Bowel ischemia describes disorders that occur when blood flow to your intestines decrease, causing severe abdominal pain.

Reuters yesterday

BSX
-0.79%
What's in Store for Boston Scientific (BSX) in Q1 Earnings?

Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.

Zacks 2 days ago

BSX
-0.79%
EW
-0.91%
14 Best 52-Week High Stocks To Invest In Now

This article delves into the examination of the 14 best 52-week high stocks to buy now. To explore more such companies that meet comparable criteria, go directly to 5 Best 52-Week High Stocks To Buy Now. The outlook for 2024 is positive for the economy and the stock market. Market conditions improved significantly in Q4 […]

Insider Monkey 3 days ago

LEN-B

CI
+0.78%
BSX
-0.79%
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable

Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.

Zacks 7 days ago

MDT
+0.14%
ABT
-0.59%
BSX
-0.79%
Boston Scientific (BSX) Faces Rising Costs, Competition

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

Zacks 8 days ago

BSX
-0.79%
SYK
-2.55%
AHCO or BSX: Which Is the Better Value Stock Right Now?

AHCO vs. BSX: Which Stock Is the Better Value Option?

Zacks 10 days ago

BSX
-0.79%
AHCO
Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module

Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the FARAPULSE™ PFA System through integration with our cardiac mapping system.

PR Newswire 11 days ago

BSX
-0.79%
11 Overvalued Stocks Insiders are Dumping Now

In this article, we will take a detailed look at the 11 Overvalued Stocks Insiders are Dumping Now. For a quick overview of such stocks, read our article 5 Overvalued Stocks Insiders are Dumping Now. Wise investors almost always keep track of corporate insider activity because paying attention to insider sentiment has proven to be a successful strategy several times […]

Insider Monkey 14 days ago

^GSPC

BSX
-0.79%
MSTR
UPDATE 1-FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics. In a regulatory filing, Boston Scientific said Axonics has also received a request for additional information from the FTC and both the companies expect to respond promptly. Boston said it now expects the deal, announced in January, to be completed in the second half of 2024 following the FTC's request, compared to its previous estimate of first half.

Reuters 14 days ago

BSX
-0.79%
FTC asks Boston Scientific for more info on $3.7B Axonics deal

The company has pushed back its expected closing date for the acquisition due to the second request from the Federal Trade Commission.

MedTech Dive 15 days ago

BSX
-0.79%
Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 24 prior to the conference call.

PR Newswire 17 days ago

BSX
-0.79%
Boston Scientific (BSX) and Scivita Medical Expand Partnership

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Zacks 21 days ago

BSX
-0.79%
CAH
-0.49%
SYK
-2.55%
Scivita Medical Expands Collaboration with Boston Scientific

Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.

PR Newswire 24 days ago

BSX
-0.79%
Abbott (ABT) Expands in Canada With First Eterna SCS Use

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

Zacks 24 days ago

NVRO

BSX
-0.79%
ABT
-0.59%
AHCO vs. BSX: Which Stock Is the Better Value Option?

AHCO vs. BSX: Which Stock Is the Better Value Option?

Zacks 27 days ago

BSX
-0.79%
AHCO
Medtronic claims win in Axonics patent row, pushes for jury trial

New rulings from a U.S. patent appeal board are the latest step in the companies’ intellectual property dispute over sacral neuromodulation devices.

MedTech Dive 28 days ago

MDT
+0.14%
BSX
-0.79%
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

Zacks last month

BSX
-0.79%
CAH
-0.49%
SYK
-2.55%
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.

Zacks last month

BSX
-0.79%
DVA

CAH
-0.49%

Performance Overview

Return	BSX	S&P 500
YTD	+16.62%	+5.06%
1-Year	+30.31%	+20.71%
3-Year	+64.80%	+19.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Boston Scientific Corporation (BSX)

FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'

Boston Scientific recalls blood-blocking agent linked to 2 deaths

UPDATE 1-FDA classifies recall of Boston Scientific device as 'most serious'

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

14 Best 52-Week High Stocks To Invest In Now

Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable

Boston Scientific (BSX) Faces Rising Costs, Competition

AHCO or BSX: Which Is the Better Value Stock Right Now?

Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module

11 Overvalued Stocks Insiders are Dumping Now

UPDATE 1-FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

FTC asks Boston Scientific for more info on $3.7B Axonics deal

Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results

Boston Scientific (BSX) and Scivita Medical Expand Partnership

Scivita Medical Expands Collaboration with Boston Scientific

Abbott (ABT) Expands in Canada With First Eterna SCS Use

AHCO vs. BSX: Which Stock Is the Better Value Option?

Medtronic claims win in Axonics patent row, pushes for jury trial

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System

Performance Overview